Correlation between BRAFV600E mutation and clinicopathological features in pediatric papillary thyroid carcinoma

被引:0
|
作者
Jiangqiao Geng [1 ,2 ]
Huanmin Wang [3 ]
Yuanhu Liu [4 ]
Jun Tai [1 ]
Yaqiong Jin [4 ]
Jie Zhang [1 ]
Lejian He [5 ]
Libing Fu [5 ]
Hong Qin [3 ]
Yingluan Song [2 ]
Jinzhu Su [2 ]
Aiying Zhang [2 ]
Xin Wen [2 ]
Yongli Guo [4 ]
Xin Ni [1 ,4 ]
机构
[1] Otolaryngology, Head and Neck Surgery, Beijing Children's Hospital, Capital Medical University,National Center for Children's Health
[2] Otolaryngology, Children's Hospital of Hebei Province
[3] Department of Surgical Oncology, Beijing Children's Hospital, Capital Medical University,National Center for Children's Health
[4] Beijing Key Laboratory for Pediatric Diseases of Otolaryngology, Head and Neck Surgery, Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University,National Center for Children's Health
[5] Department of Pathology, Beijing Children's Hospital, Capital Medical University,National Center for Children's Health
关键词
D O I
暂无
中图分类号
R736.1 [甲状腺肿瘤];
学科分类号
100214 ;
摘要
In adults, the presence of the BRAFV600Emutation in papillary thyroid cancer(PTC) has been demonstrated to be strongly associated with aggressive cancer-cell characteristics and poor patient prognosis. In contrast, the frequency of this mutation in pediatric PTC has undergone limited study, and the few available estimates range from 0 to 63%. Furthermore, the role of the BRAFV600Emutation in pediatric PTC is controversial; thus, the present study aimed to investigate the prevalence and role of the BRAFV600Emutation in48 pediatric patients with PTC, aged 3–13 years. Of these patients, 41 were diagnosed with classic PTC, five were found to have a follicular variant of PTC, and two to exhibit a diffuse sclerosing PTC variant. The BRAFV600Emutation was identified to be present in 35.4% of the 48 analyzed patients, and in 41.5% of the patients diagnosed with classical PTC. Furthermore, the presence of the BRAFV600Emutation was found to be associated with a patient age at diagnosis of less than ten years(P=0.011), the performance of a thyroidectomy(P=0.03), exhibited tumor multifocality(P=0.02) and/or extra-thyroidal invasion(P=0.003), and both a low MACIS(Metastases, Age, Completeness of resection, Invasion, Size)(P=0.036) and AMES(Age, Metastasis, Extent of tumor,Size)(P=0.001)score. Together, these data suggest that the presence of the BRAFV600Emutation may be negatively correlated with partial aggressive clinicopathological features of pediatric PTC.
引用
收藏
页码:729 / 738
页数:10
相关论文
共 50 条
  • [21] Accuracy and Reproducibility of Histologic Features Predictive of BRAFV600E Mutation in Papillary Thyroid Carcinoma
    Virk, R. K.
    Finkelstein, A.
    Prasad, A.
    Hui, P.
    Chhieng, D.
    Theoharis, C.
    Gibson, J.
    Roman, S.
    Prasad, M.
    [J]. LABORATORY INVESTIGATION, 2012, 92 : 150A - 151A
  • [22] Correlation between BRAFv600E mutation and clinicopathological features and short-term curative effect in intermediate and high-risk papillary thyroid carcinoma
    Zhu Guoquan
    Ou Yangwei
    Feng Huijuan
    Wu Juqing
    Chen Pan
    Wang Jing
    Pan Liqin
    Deng Yuying
    [J]. JOURNAL OF NUCLEAR MEDICINE, 2019, 60
  • [23] Morphological features predictive for BRAFV600E mutation in papillary thyroid microcarcinomas
    Nechifor-Boila, Adela Corina
    Szasz, Emoke-Andrea
    Descotes, Francoise
    Berger, Nicole
    Zahan, Ancuta Elena
    Loghin, Andrada
    Ceteras, Delia Maria
    Borda, Angela
    [J]. ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY, 2018, 59 (03): : 747 - 753
  • [24] Predictive Factors for Level V Lymph Node Metastases in Papillary Thyroid Carcinoma with BRAFV600E Mutation and Clinicopathological Features
    Li, Gui-you
    Tani, Hai-long
    Chen, Pei
    Hu, Hui-Yu
    Liui, Mian
    Ou-yang, Deng-jie
    Khushbui, Rooh-afza
    Pun, Deepak
    Li, Jin-dong
    Zhang, Zhi-peng
    Yang, Qiong
    Huang, Peng
    Chang, Shi
    [J]. CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 3371 - 3378
  • [25] BRAFV600E and Recurrence in Papillary Carcinoma Thyroid
    Kumari, N.
    George, N.
    Shukla, P.
    Vishwakarma, R.
    Agarwal, A.
    Krishnani, N.
    [J]. JOURNAL OF MOLECULAR DIAGNOSTICS, 2015, 17 (06): : 827 - 827
  • [26] Animal Model of the Papillary Thyroid Carcinoma Induced by BRAFV600E Mutation
    Rusinek, D.
    Chmielik, E.
    Kowal, M.
    Swierniak, M.
    Kowalska, M.
    Oczko-Wojciechowska, M.
    Przeorek, C.
    Widlak, W.
    Jarzab, B.
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : S166 - S167
  • [27] Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation
    Huang, Yongbo
    Liao, Denghui
    Pan, Lingxiao
    Ye, Runyi
    Li, Xiaoxi
    Wang, Shenming
    Ye, Caisheng
    Chen, Liuhua
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 168 (05) : 675 - 681
  • [28] The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma
    Scheffel, Rafael Selbach
    de Cristo, Ana Patricia
    Romitti, Mirian
    Ferreira Vargas, Carla Vaz
    Ceolin, Lucien
    Zanella, Andre B.
    Dora, Jose Miguel
    Maia, Ana Luiza
    [J]. ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2020, 64 (06): : 751 - 757
  • [29] BRAFV600E mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: A meta-analysis
    Ma, Yu-jia
    Deng, Xiu-ling
    Li, Hui-qing
    [J]. JOURNAL OF HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY-MEDICAL SCIENCES, 2015, 35 (04) : 591 - 599
  • [30] BRAFV600E Mutation and Its Association with Clinicopathological Features of Papillary Thyroid Microcarcinoma: A Meta-Analysis
    马禹佳
    邓秀玲
    黎慧清
    [J]. Current Medical Science, 2015, 35 (04) : 591 - 599